Development and validation of the mpox stigma scale

Background Few validated brief scales are available to measure constructs that may hinder mpox-related prevention and care engagement, such as knowledge and stigma. Both are highly salient barriers to infectious disease care and disease understanding, precursors to evaluating one's risk and nee...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC public health 2024-09, Vol.24 (1)
Hauptverfasser: Budhwani, Henna, Yigit, Ibrahim, Stocks, Jacob B, Stoner, Marie C.D, Browne, Erica, Pettifor, Audrey E, Hightow-Weidman, Lisa B
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 1
container_start_page
container_title BMC public health
container_volume 24
creator Budhwani, Henna
Yigit, Ibrahim
Stocks, Jacob B
Stoner, Marie C.D
Browne, Erica
Pettifor, Audrey E
Hightow-Weidman, Lisa B
description Background Few validated brief scales are available to measure constructs that may hinder mpox-related prevention and care engagement, such as knowledge and stigma. Both are highly salient barriers to infectious disease care and disease understanding, precursors to evaluating one's risk and need to, for example, accept vaccination. To address this gap, we developed and validated the Mpox Stigma Scale (MSS) and Mpox Knowledge Scale (MKS). Methods As part of a full-scale clinical trial, we offered an optional mpox survey to participants who self-identified as African American or Black, were 18-29 years old, and lived in Alabama, Georgia, or North Carolina (2023, N = 330). We calculated psychometric properties through confirmatory factor analyses (CFA) and applied Comparative Fit Index (CFI), Goodness of Fit Index (GFI), and Tucker-Lewis Index (TLI) values equal to or exceeding 0.90 and Root Mean Square Error of Approximation (RMSEA) and Standardized Root Mean Square Residual (SRMR) values less than 0.08 to determine adequate model fit. We computed internal reliability using Cronbach's alpha and calculated Pearson or Spearman correlation coefficients between the MSS and MKS and related variables. Results For the MSS, CFA results showed that the one-factor model fit the data well ([chl].sup.2(df = 5, N = 330) = 34.962, CFI = 0.97, GFI = 0.99, TLI = 0.94, RMSEA = 0.13, SRMR = 0.03). For the MKS, the one-factor model provided a good fit to the data ([chl].sup.2(df = 6, N = 330) = 8.44, CFI = 0.99, GFI = 0.99, TLI = 0.95, RMSEA = 0.15, SRMR = 0.02). Cronbach's alphas were MSS = 0.91 and MKS = 0.83, suggesting good to excellent reliability. The MSS was correlated with the MKS (r = .55, p < .001), stigmatizing attitudes (r = .24, p < .001), attitudes towards mpox vaccination (r=-.12, p = .030), and worry about contracting mpox (r = .44, p < .001). The MKS was correlated with worry about contracting mpox (r = .30, p < .001) and mpox disclosure (r=-.16, p = .003). Conclusions The MSS and MKS are reliable and valid tools for public health practice, treatment and prevention research, and behavioral science. Further validation is warranted across populations and geographic locations. Trial Registration ClinicalTrials.gov NCT05490329. Keywords: Mpox, Stigma, Monkeypox, Scale validation, Psychometric Properties
doi_str_mv 10.1186/s12889-024-19868-x
format Article
fullrecord <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A808332000</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A808332000</galeid><sourcerecordid>A808332000</sourcerecordid><originalsourceid>FETCH-LOGICAL-g670-7a0a1d5f54520ba6b00232689b5a8079fc82e7707a5fb58ef1c60e50b82882553</originalsourceid><addsrcrecordid>eNptT01LAzEUDKJgrf4BTwHPqS_ZTfL2WOonFLz0Xt5mkzWyuykmlP58F_TQg8xhHsPMPIaxewkrKdE8ZqkQGwGqFrJBg-J0wRaytlKoWuPl2X3NbnL-ApAWtVqw6skf_ZAOo58Kp6njRxpiRyWmiafAy6fn4yGdeC6xH4lnR4O_ZVeBhuzv_njJdi_Pu82b2H68vm_WW9EbC8ISkOx00LVW0JJpAVSlDDatJgTbBIfKWwuWdGg1-iCdAa-hxXmK0rpasoff2n7-uY9TSOWb3Biz268RsKoUAMyu1T-uGZ0fo0uTD3HWzwI_nO9VRA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Development and validation of the mpox stigma scale</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Springer Nature - Complete Springer Journals</source><source>PubMed Central</source><source>Springer Nature OA/Free Journals</source><creator>Budhwani, Henna ; Yigit, Ibrahim ; Stocks, Jacob B ; Stoner, Marie C.D ; Browne, Erica ; Pettifor, Audrey E ; Hightow-Weidman, Lisa B</creator><creatorcontrib>Budhwani, Henna ; Yigit, Ibrahim ; Stocks, Jacob B ; Stoner, Marie C.D ; Browne, Erica ; Pettifor, Audrey E ; Hightow-Weidman, Lisa B</creatorcontrib><description>Background Few validated brief scales are available to measure constructs that may hinder mpox-related prevention and care engagement, such as knowledge and stigma. Both are highly salient barriers to infectious disease care and disease understanding, precursors to evaluating one's risk and need to, for example, accept vaccination. To address this gap, we developed and validated the Mpox Stigma Scale (MSS) and Mpox Knowledge Scale (MKS). Methods As part of a full-scale clinical trial, we offered an optional mpox survey to participants who self-identified as African American or Black, were 18-29 years old, and lived in Alabama, Georgia, or North Carolina (2023, N = 330). We calculated psychometric properties through confirmatory factor analyses (CFA) and applied Comparative Fit Index (CFI), Goodness of Fit Index (GFI), and Tucker-Lewis Index (TLI) values equal to or exceeding 0.90 and Root Mean Square Error of Approximation (RMSEA) and Standardized Root Mean Square Residual (SRMR) values less than 0.08 to determine adequate model fit. We computed internal reliability using Cronbach's alpha and calculated Pearson or Spearman correlation coefficients between the MSS and MKS and related variables. Results For the MSS, CFA results showed that the one-factor model fit the data well ([chl].sup.2(df = 5, N = 330) = 34.962, CFI = 0.97, GFI = 0.99, TLI = 0.94, RMSEA = 0.13, SRMR = 0.03). For the MKS, the one-factor model provided a good fit to the data ([chl].sup.2(df = 6, N = 330) = 8.44, CFI = 0.99, GFI = 0.99, TLI = 0.95, RMSEA = 0.15, SRMR = 0.02). Cronbach's alphas were MSS = 0.91 and MKS = 0.83, suggesting good to excellent reliability. The MSS was correlated with the MKS (r = .55, p &lt; .001), stigmatizing attitudes (r = .24, p &lt; .001), attitudes towards mpox vaccination (r=-.12, p = .030), and worry about contracting mpox (r = .44, p &lt; .001). The MKS was correlated with worry about contracting mpox (r = .30, p &lt; .001) and mpox disclosure (r=-.16, p = .003). Conclusions The MSS and MKS are reliable and valid tools for public health practice, treatment and prevention research, and behavioral science. Further validation is warranted across populations and geographic locations. Trial Registration ClinicalTrials.gov NCT05490329. Keywords: Mpox, Stigma, Monkeypox, Scale validation, Psychometric Properties</description><identifier>ISSN: 1471-2458</identifier><identifier>EISSN: 1471-2458</identifier><identifier>DOI: 10.1186/s12889-024-19868-x</identifier><language>eng</language><publisher>BioMed Central Ltd</publisher><subject>Evaluation ; Health aspects ; Health literacy ; Human monkeypox ; Methods ; Public opinion ; Questionnaires ; Stigma (Social psychology)</subject><ispartof>BMC public health, 2024-09, Vol.24 (1)</ispartof><rights>COPYRIGHT 2024 BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,27903,27904</link.rule.ids></links><search><creatorcontrib>Budhwani, Henna</creatorcontrib><creatorcontrib>Yigit, Ibrahim</creatorcontrib><creatorcontrib>Stocks, Jacob B</creatorcontrib><creatorcontrib>Stoner, Marie C.D</creatorcontrib><creatorcontrib>Browne, Erica</creatorcontrib><creatorcontrib>Pettifor, Audrey E</creatorcontrib><creatorcontrib>Hightow-Weidman, Lisa B</creatorcontrib><title>Development and validation of the mpox stigma scale</title><title>BMC public health</title><description>Background Few validated brief scales are available to measure constructs that may hinder mpox-related prevention and care engagement, such as knowledge and stigma. Both are highly salient barriers to infectious disease care and disease understanding, precursors to evaluating one's risk and need to, for example, accept vaccination. To address this gap, we developed and validated the Mpox Stigma Scale (MSS) and Mpox Knowledge Scale (MKS). Methods As part of a full-scale clinical trial, we offered an optional mpox survey to participants who self-identified as African American or Black, were 18-29 years old, and lived in Alabama, Georgia, or North Carolina (2023, N = 330). We calculated psychometric properties through confirmatory factor analyses (CFA) and applied Comparative Fit Index (CFI), Goodness of Fit Index (GFI), and Tucker-Lewis Index (TLI) values equal to or exceeding 0.90 and Root Mean Square Error of Approximation (RMSEA) and Standardized Root Mean Square Residual (SRMR) values less than 0.08 to determine adequate model fit. We computed internal reliability using Cronbach's alpha and calculated Pearson or Spearman correlation coefficients between the MSS and MKS and related variables. Results For the MSS, CFA results showed that the one-factor model fit the data well ([chl].sup.2(df = 5, N = 330) = 34.962, CFI = 0.97, GFI = 0.99, TLI = 0.94, RMSEA = 0.13, SRMR = 0.03). For the MKS, the one-factor model provided a good fit to the data ([chl].sup.2(df = 6, N = 330) = 8.44, CFI = 0.99, GFI = 0.99, TLI = 0.95, RMSEA = 0.15, SRMR = 0.02). Cronbach's alphas were MSS = 0.91 and MKS = 0.83, suggesting good to excellent reliability. The MSS was correlated with the MKS (r = .55, p &lt; .001), stigmatizing attitudes (r = .24, p &lt; .001), attitudes towards mpox vaccination (r=-.12, p = .030), and worry about contracting mpox (r = .44, p &lt; .001). The MKS was correlated with worry about contracting mpox (r = .30, p &lt; .001) and mpox disclosure (r=-.16, p = .003). Conclusions The MSS and MKS are reliable and valid tools for public health practice, treatment and prevention research, and behavioral science. Further validation is warranted across populations and geographic locations. Trial Registration ClinicalTrials.gov NCT05490329. Keywords: Mpox, Stigma, Monkeypox, Scale validation, Psychometric Properties</description><subject>Evaluation</subject><subject>Health aspects</subject><subject>Health literacy</subject><subject>Human monkeypox</subject><subject>Methods</subject><subject>Public opinion</subject><subject>Questionnaires</subject><subject>Stigma (Social psychology)</subject><issn>1471-2458</issn><issn>1471-2458</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNptT01LAzEUDKJgrf4BTwHPqS_ZTfL2WOonFLz0Xt5mkzWyuykmlP58F_TQg8xhHsPMPIaxewkrKdE8ZqkQGwGqFrJBg-J0wRaytlKoWuPl2X3NbnL-ApAWtVqw6skf_ZAOo58Kp6njRxpiRyWmiafAy6fn4yGdeC6xH4lnR4O_ZVeBhuzv_njJdi_Pu82b2H68vm_WW9EbC8ISkOx00LVW0JJpAVSlDDatJgTbBIfKWwuWdGg1-iCdAa-hxXmK0rpasoff2n7-uY9TSOWb3Biz268RsKoUAMyu1T-uGZ0fo0uTD3HWzwI_nO9VRA</recordid><startdate>20240910</startdate><enddate>20240910</enddate><creator>Budhwani, Henna</creator><creator>Yigit, Ibrahim</creator><creator>Stocks, Jacob B</creator><creator>Stoner, Marie C.D</creator><creator>Browne, Erica</creator><creator>Pettifor, Audrey E</creator><creator>Hightow-Weidman, Lisa B</creator><general>BioMed Central Ltd</general><scope/></search><sort><creationdate>20240910</creationdate><title>Development and validation of the mpox stigma scale</title><author>Budhwani, Henna ; Yigit, Ibrahim ; Stocks, Jacob B ; Stoner, Marie C.D ; Browne, Erica ; Pettifor, Audrey E ; Hightow-Weidman, Lisa B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g670-7a0a1d5f54520ba6b00232689b5a8079fc82e7707a5fb58ef1c60e50b82882553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Evaluation</topic><topic>Health aspects</topic><topic>Health literacy</topic><topic>Human monkeypox</topic><topic>Methods</topic><topic>Public opinion</topic><topic>Questionnaires</topic><topic>Stigma (Social psychology)</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Budhwani, Henna</creatorcontrib><creatorcontrib>Yigit, Ibrahim</creatorcontrib><creatorcontrib>Stocks, Jacob B</creatorcontrib><creatorcontrib>Stoner, Marie C.D</creatorcontrib><creatorcontrib>Browne, Erica</creatorcontrib><creatorcontrib>Pettifor, Audrey E</creatorcontrib><creatorcontrib>Hightow-Weidman, Lisa B</creatorcontrib><jtitle>BMC public health</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Budhwani, Henna</au><au>Yigit, Ibrahim</au><au>Stocks, Jacob B</au><au>Stoner, Marie C.D</au><au>Browne, Erica</au><au>Pettifor, Audrey E</au><au>Hightow-Weidman, Lisa B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development and validation of the mpox stigma scale</atitle><jtitle>BMC public health</jtitle><date>2024-09-10</date><risdate>2024</risdate><volume>24</volume><issue>1</issue><issn>1471-2458</issn><eissn>1471-2458</eissn><abstract>Background Few validated brief scales are available to measure constructs that may hinder mpox-related prevention and care engagement, such as knowledge and stigma. Both are highly salient barriers to infectious disease care and disease understanding, precursors to evaluating one's risk and need to, for example, accept vaccination. To address this gap, we developed and validated the Mpox Stigma Scale (MSS) and Mpox Knowledge Scale (MKS). Methods As part of a full-scale clinical trial, we offered an optional mpox survey to participants who self-identified as African American or Black, were 18-29 years old, and lived in Alabama, Georgia, or North Carolina (2023, N = 330). We calculated psychometric properties through confirmatory factor analyses (CFA) and applied Comparative Fit Index (CFI), Goodness of Fit Index (GFI), and Tucker-Lewis Index (TLI) values equal to or exceeding 0.90 and Root Mean Square Error of Approximation (RMSEA) and Standardized Root Mean Square Residual (SRMR) values less than 0.08 to determine adequate model fit. We computed internal reliability using Cronbach's alpha and calculated Pearson or Spearman correlation coefficients between the MSS and MKS and related variables. Results For the MSS, CFA results showed that the one-factor model fit the data well ([chl].sup.2(df = 5, N = 330) = 34.962, CFI = 0.97, GFI = 0.99, TLI = 0.94, RMSEA = 0.13, SRMR = 0.03). For the MKS, the one-factor model provided a good fit to the data ([chl].sup.2(df = 6, N = 330) = 8.44, CFI = 0.99, GFI = 0.99, TLI = 0.95, RMSEA = 0.15, SRMR = 0.02). Cronbach's alphas were MSS = 0.91 and MKS = 0.83, suggesting good to excellent reliability. The MSS was correlated with the MKS (r = .55, p &lt; .001), stigmatizing attitudes (r = .24, p &lt; .001), attitudes towards mpox vaccination (r=-.12, p = .030), and worry about contracting mpox (r = .44, p &lt; .001). The MKS was correlated with worry about contracting mpox (r = .30, p &lt; .001) and mpox disclosure (r=-.16, p = .003). Conclusions The MSS and MKS are reliable and valid tools for public health practice, treatment and prevention research, and behavioral science. Further validation is warranted across populations and geographic locations. Trial Registration ClinicalTrials.gov NCT05490329. Keywords: Mpox, Stigma, Monkeypox, Scale validation, Psychometric Properties</abstract><pub>BioMed Central Ltd</pub><doi>10.1186/s12889-024-19868-x</doi></addata></record>
fulltext fulltext
identifier ISSN: 1471-2458
ispartof BMC public health, 2024-09, Vol.24 (1)
issn 1471-2458
1471-2458
language eng
recordid cdi_gale_infotracmisc_A808332000
source DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Springer Nature - Complete Springer Journals; PubMed Central; Springer Nature OA/Free Journals
subjects Evaluation
Health aspects
Health literacy
Human monkeypox
Methods
Public opinion
Questionnaires
Stigma (Social psychology)
title Development and validation of the mpox stigma scale
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T18%3A58%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20and%20validation%20of%20the%20mpox%20stigma%20scale&rft.jtitle=BMC%20public%20health&rft.au=Budhwani,%20Henna&rft.date=2024-09-10&rft.volume=24&rft.issue=1&rft.issn=1471-2458&rft.eissn=1471-2458&rft_id=info:doi/10.1186/s12889-024-19868-x&rft_dat=%3Cgale%3EA808332000%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A808332000&rfr_iscdi=true